{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:40:57Z","timestamp":1794523257858,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":143,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","award":["Chiesi Farmaceutici"],"award-info":[{"award-number":["Chiesi Farmaceutici"]}],"id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A better understanding of Fabry Disease (FD) in terms of diagnostic journey, patient profile and use of available treatments remains topical. The Global buRden and treatment trajectOries in Italian patients with Fabry disease: a retrospective longitUdinal and cross-sectioNal study-GROUND was designed to provide a comprehensive overview of a real-world FD Italian cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, multicenter, longitudinal and cross-sectional study of adult FD patients of either sex with \u2265\u20093 years of follow-up. Severe\/fatal events from birth to last visit was the composite primary outcome. Secondary outcomes were disease progression measured by FAbry STabilization indEX (FASTEX); disease activity assessed by clinically significant events\/FD related symptoms; time from first manifestation to diagnosis; treatment trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      199 patients, 73 males and 126 females, 169 classic and 30 late-onset phenotypes, were enrolled at 8 Italian centers. Mean time from first FD symptom to diagnosis was 5.03 years (range 0.00-43.90), with a median of 0.64 years (range 0-19.29) from diagnosis to start of FD specific treatment. Initial manifestations were chronic pain (18.1%), angiokeratomas (13.1%), acroparesthesia and abdominal pain (12.5%), or left ventricular hypertrophy (LVH) (8.5%). 143 missense\/nonsense GLA variants were identified. 82% patients were actively treated with one of the FD specific therapies, 24% had switched\u2009\u2265\u20091 treatment, while 5% had definitively stopped treatment. The primary outcome was experienced by 31.7% of patients for a total of 85 severe\/fatal events, mainly in the treated cohort: 20.6% had a cardiac event, 11.1% a cerebral event 7.5% patients experienced a renal event, while fatal events occurred in 7 patients (3.5%). 88.9% reported\u2009\u2265\u20091 clinically significant event, with detection\/worsening of LVH being the most common (41.2%). Estimated Glomerular Filtration rate (eGFR) slopes in last 1\u20133 years of follow-up were \u2212\u20092.07\u00a0ml\/min\/m\n                      <jats:sup>2<\/jats:sup>\n                      (SE: 1.38) and \u2212\u20090.76 and \u2212\u20092.07\u00a0ml\/min\/m\n                      <jats:sup>2<\/jats:sup>\n                      (SE: 1.75) in classic males and females, respectively. Long-term FASTEX identified 31.1% of patients as being unstable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even though FD patients were promptly treated, severe clinical events occurred in about 30%, mainly classic males, highlighting the need for sensitive tools assessing outcomes and novel therapeutic options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04370-x","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:46:57Z","timestamp":1780292817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world outcomes of Fabry disease in Italian excellence centers: the ground study"],"prefix":"10.1186","volume":"21","author":[{"given":"Iacopo","family":"Olivotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Umberto","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Tuttolomondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verrecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Ingrassia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Armaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"4370_CR1","doi-asserted-by":"publisher","unstructured":"Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae.) Arch Dermatol Res. 1898;43:187\u2013200. https:\/\/doi.org\/10.1007\/BF01986897.","DOI":"10.1007\/BF01986897"},{"key":"4370_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","volume":"10","author":"W Anderson","year":"1898","unstructured":"Anderson W. A Case of Angeio-Keratoma. Br J Dermatol. 1898;10:113\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.1898.tb16317.x.","journal-title":"Br J Dermatol"},{"key":"4370_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30. PMID: 21092187; PMCID: PMC3009617.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4370_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/ijms26020473","volume":"26","author":"M Anania","year":"2025","unstructured":"Anania M, Pieruzzi F, Giacalone I, Trezzi B, Marsana EM, Roggero L, Francofonte D, Stefanoni M, Vinci M, Zizzo C, Zora M, Di Chiara T, Duro G, Duro G, Colomba P. Identification of Four New Mutations in the GLA Gene Associated with Anderson-Fabry Disease. Int J Mol Sci. 2025;26(2):473. https:\/\/doi.org\/10.3390\/ijms26020473. PMID: 39859188; PMCID: PMC11764669.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4370_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.201208152","volume":"199","author":"FM Platt","year":"2012","unstructured":"Platt FM, van der Boland B. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723\u201334. https:\/\/doi.org\/10.1083\/jcb.201208152. PMID: 23185029; PMCID: PMC3514785.","journal-title":"J Cell Biol"},{"key":"4370_CR6","doi-asserted-by":"publisher","unstructured":"Pieroni M, Namdar M, Olivotto I, Desnick RJ. Anderson-Fabry disease management: role of the cardiologist. Eur Heart J. 2024;45(16):1395\u20131409. https:\/\/doi.org\/10.1093\/eurheartj\/ehae148. PMID: 38486361.","DOI":"10.1093\/eurheartj\/ehae148"},{"issue":"1","key":"4370_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340. https:\/\/doi.org\/10.1086\/504601. Epub 2006 Apr 28. PMID: 16773563; PMCID: PMC1474133.","journal-title":"Am J Hum Genet"},{"key":"4370_CR8","first-page":"100562","volume":"22","author":"T Sawada","year":"2020","unstructured":"Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T, Tajima G, Sawada H, Mastumoto S, Endo F, Hirose S, Nakamura K. Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep. 2020;22:100562. PMID: 31956509; PMCID: PMC6961758.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"4370_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, Young K, Oram RA, Weedon MN. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023;60(4):391\u20136. https:\/\/doi.org\/10.1136\/jmg-2022-108523. Epub 2022 Aug 17. PMID: 35977816; PMCID: PMC10086508.","journal-title":"J Med Genet"},{"key":"4370_CR10","doi-asserted-by":"publisher","unstructured":"Laney DA, Fernhoff PM. Diagnosis of Fabry disease via analysis of family history. J Genet Couns. 2008;17(1):79\u201383. https:\/\/doi.org\/10.1007\/s10897-007-9128-x. Epub 2008 Jan 3. PMID: 18172746.","DOI":"10.1007\/s10897-007-9128-x"},{"key":"4370_CR11","doi-asserted-by":"publisher","unstructured":"El-Abassi R, Singhal D, England JD. Fabry\u2019s disease. J Neurol Sci. 2014;344(1\u20132):5\u201319. https:\/\/doi.org\/10.1016\/j.jns.2014.06.029. Epub 2014 Jun 21. PMID: 25106696.","DOI":"10.1016\/j.jns.2014.06.029"},{"issue":"1","key":"4370_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44\u201354. https:\/\/doi.org\/10.1111\/cge.12613. Epub 2015 Jun 22. PMID: 25974833.","journal-title":"Clin Genet"},{"issue":"4","key":"4370_CR13","doi-asserted-by":"publisher","first-page":"e0193550","DOI":"10.1371\/journal.pone.0193550","volume":"13","author":"L Lavalle","year":"2018","unstructured":"Lavalle L, Thomas AS, Beaton B, Ebrahim H, Reed M, Ramaswami U, Elliott P, Mehta AB, Hughes DA. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. PLoS ONE. 2018;13(4):e0193550. https:\/\/doi.org\/10.1371\/journal.pone.0193550. PMID: 29621274; PMCID: PMC5886405.","journal-title":"PLoS ONE"},{"issue":"3","key":"4370_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","volume":"21","author":"L Palaiodimou","year":"2023","unstructured":"Palaiodimou L, Kokotis P, Zompola C, Papagiannopoulou G, Bakola E, Papadopoulou M, Zouvelou V, Petras D, Vlachopoulos C, Tsivgoulis G. Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review. Curr Neuropharmacol. 2023;21(3):440\u201356. PMID: 35652398; PMCID: PMC10207921.","journal-title":"Curr Neuropharmacol"},{"key":"4370_CR15","doi-asserted-by":"publisher","unstructured":"Burlina A, Brand E, Hughes D, Kantola I, Kr\u04d3mer J, Nowak A, T\u00f8ndel C, Wanner C, Spada M. An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Mol Genet Metab. 2023;139(2):107585. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107585. Epub 2023 Apr 17. PMID: 37207471.","DOI":"10.1016\/j.ymgme.2023.107585"},{"issue":"6","key":"4370_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Fabry Disease: The Current Treatment Landscape. Drugs. 2021;81(6):635\u201345. https:\/\/doi.org\/10.1007\/s40265-021-01486-1. Epub 2021 Mar 15. PMID: 33721270; PMCID: PMC8102455.","journal-title":"Drugs"},{"key":"4370_CR17","doi-asserted-by":"publisher","first-page":"101218","DOI":"10.1016\/j.ymgmr.2025.101218","volume":"43","author":"R Giugliani","year":"2025","unstructured":"Giugliani R, Politei J, Martins A, Murillo N, Rozenfeld P, Lopera M, Salgado S, Quir\u00f3s G, Marques C, Vieira O, Amartino H, Perretta F, Marques E, Silva S, Brooks J, Titievsky L, Villalobos J, Braga C, Pe\u00f1aranda HA. Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards. Mol Genet Metab Rep. 2025;43:101218. https:\/\/doi.org\/10.1016\/j.ymgmr.2025.101218. PMID: 40276562; PMCID: PMC12020846.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"4370_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2019","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and Investigational Therapeutics for Fabry Disease. Kidney Int Rep. 2019;5(4):407\u201313. PMID: 32274449; PMCID: PMC7136345.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"4370_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/diagnostics15020139","volume":"15","author":"C Tognola","year":"2025","unstructured":"Tognola C, Ruzzenenti G, Maloberti A, Varrenti M, Mazzone P, Giannattasio C, Guarracini F. Anderson-Fabry Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification, and Therapeutic Strategies. Diagnostics (Basel). 2025;15(2):139. https:\/\/doi.org\/10.3390\/diagnostics15020139. PMID: 39857023; PMCID: PMC11763368.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"4370_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, K\u00f6rver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41(1):141\u20139. https:\/\/doi.org\/10.1007\/s10545-017-0095-6. Epub 2017 Oct 16. PMID: 29039131; PMCID: PMC5786653.","journal-title":"J Inherit Metab Dis"},{"key":"4370_CR21","doi-asserted-by":"publisher","unstructured":"Nowicki M, Bazan-Socha S, B\u0142a\u017cejewska-Hy\u017corek B, K\u0142opotowski MM, Komar M, Kusztal MA, Liberek T, Ma\u0142yszko J, Mizia-Stec K, Oko-Sarnowska Z, Pawlaczyk K, Podolec P, S\u0142awek J, Polish Fabry Disease Collaborative Group. A review and recommendations for oral chaperone therapy in adult patients with Fabry disease. Orphanet J Rare Dis. 2024;19(1):16. https:\/\/doi.org\/10.1186\/s13023-024-03028-w. Erratum in: Orphanet J Rare Dis. 2024 Mar 28;19(1):139. doi: 10.1186\/s13023-024-03140-x. PMID: 38238782; PMCID: PMC10797794.","DOI":"10.1186\/s13023-024-03028-w"},{"key":"4370_CR22","doi-asserted-by":"publisher","unstructured":"Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65(4):299\u2013307. https:\/\/doi.org\/10.1111\/j.1399-0004.2004.00219.x. PMID: 15025723.","DOI":"10.1111\/j.1399-0004.2004.00219.x"},{"issue":"5","key":"4370_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ckj\/sfw082","volume":"9","author":"R Mignani","year":"2016","unstructured":"Mignani R, Pieruzzi F, Berri F, Burlina A, Chinea B, Gallieni M, Pieroni M, Salviati A, Spada M. FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease. Clin Kidney J. 2016;9(5):739\u201347. https:\/\/doi.org\/10.1093\/ckj\/sfw082. Epub 2016 Sep 9. PMID: 27679722; PMCID: PMC5036909.","journal-title":"Clin Kidney J"},{"key":"4370_CR24","first-page":"57","volume":"21","author":"A Holmes","year":"2015","unstructured":"Holmes A, Laney D. A Retrospective Survey Studying the Impact of Fabry Disease on Pregnancy. JIMD Rep. 2015;21:57\u201363. doi: 10.1007\/8904_2014_384. Epub 2015 Feb 22. PMID: 25701267; PMCID: PMC4470955.","journal-title":"JIMD Rep"},{"key":"4370_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejim.2016.03.015","volume":"32","author":"E Verrecchia","year":"2016","unstructured":"Verrecchia E, Zampetti A, Antuzzi D, Ricci R, Ferri L, Morrone A, Feliciani C, Dagna L, Manna R. The impact of fever\/hyperthermia in the diagnosis of Fabry: A retrospective analysis. Eur J Intern Med. 2016;32:26\u201330. Epub 2016 Apr 12. PMID: 27083555.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"4370_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/ijms22010206","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Sousa N, Cunha D. Fabry Disease Therapy: State-of-the-Art and Current Challenges. Int J Mol Sci. 2020;22(1):206. https:\/\/doi.org\/10.3390\/ijms22010206. PMID: 33379210; PMCID: PMC7794923.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4370_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szyma\u0144ska A, T\u00f8ndel C, Viana-Baptista M, Weidemann F, Hilz MJ. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203. https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.004. Epub 2018 Jun 12. PMID: 30017653.","journal-title":"Mol Genet Metab"},{"key":"4370_CR28","doi-asserted-by":"publisher","unstructured":"Auray-Blais, Auray-Blais C, Lavoie P, Martineau T, Ntumba GK, Gamrani M, Khan A, Altarescu G, Lehman A, Goker-Alpan O, Nowak A, West ML, Bichet DG. Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy. Bioanalysis. 2023;15(23):1421\u20131437. https:\/\/doi.org\/10.4155\/bio-2023-0160. Epub 2023 Oct 17. PMID: 37847061.","DOI":"10.4155\/bio-2023-0160"},{"key":"4370_CR29","doi-asserted-by":"publisher","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122\u201338. https:\/\/doi.org\/10.1097\/00005792-200203000-00003. PMID: 11889412.","DOI":"10.1097\/00005792-200203000-00003"},{"key":"4370_CR30","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.ymgmr.2025.101215","volume":"43","author":"U Ramaswami","year":"2025","unstructured":"Ramaswami U, Pintos-Morell G, Kampmann C, Nicholls K, Niu DM, Reisin R, West ML, Anagnostopoulou C, Botha J, Jazukeviciene D, Schenk J, Hughes DA, Giugliani R. Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy. Mol Genet Metab Rep. 2025;43:101215. https:\/\/doi.org\/10.1016\/j.ymgmr.2025.101215. PMID: 40276560; PMCID: PMC12018052.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04370-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:12:24Z","timestamp":1792451544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04370-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4370"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04370-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki, ICH E6 Good Clinical Practice principles and all applicable regulations. The study protocol was approved by the Ethics Committees of all participating centers, including: Comitato Etico Federico II Cardarelli (Naples, Italy), Comitato Etico AST Brianza (Italy), Comitato Etico della Romagna (Italy), Comitato Etico Policlinico Gemelli (Rome, Italy), Comitato Etico Palermo 1 (Italy), Comitato Etico Regione Toscana Area Vasta Sud Est (Italy), and Comitato Etico Area Vasta Centro (Italy). Written informed consent was obtained from all living patients before any study-related procedures. For deceased or untraceable patients, only retrospective non-genetic data were used in accordance with local regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RM declares no conflicts of interest related to this study. FP declares no conflicts of interest related to this study. EV declares no conflicts of interest related to this study. IO declares no conflicts of interest related to this study. FU declares no conflicts of interest related to this study. AT declares no conflicts of interest related to this study. DN declares no conflicts of interest related to this study. MP declares no conflicts of interest related to this study. AP declares no conflicts of interest related to this study. AA was an employee at Chiesi Italia SpA during this study. EI is an employee at Chiesi Italia Spa.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"365"}}